Enhancing pathways to therapeutic development with clinical biomarkers

Gregory J Downing¹

• ¹Office of Science Policy and Planning, Office of Science Policy, Office of the Director, National Institutes of Health, Bethesda, MD, USA. gd34f@nih.gov